Total Packaging Papers shipments were 207,700 tons, 3.1 percent lower than February 2017. Bag & Sack shipments were down 8.6 percent year-to-date and Multiwall shipments were down 14.5 percent, while Food Wrapping shipments and Converting shipments were both down less than 1 percent. The operating rate for February increased to 88.5 percent from 84.3 percent in January. Inventories were 175,600 tons, up 2.2 percent since January.
http://afandpa.org/media/news/2018/03/16/american-forest-paper-association-releases-february-2018-u.s.-packaging-papers-specialty-packaging-monthly-report
Related Posts
Third Quarter Financial Results Highlights: *Earnings before interest, taxes, depreciation and amortization ("EBITDA") from ongoing operations for Aluminum Extrusions of $16.5 million was $0.1 million higher than the third quarter of 2019 *EBITDA from ongoing operations for PE Films of $6.0 million was $4.2 million lower than the third quarter of 2019 *EBITDA from ongoing operations for Flexible Packaging Films of $9.5 million was $5.2 million higher than the third quarter of 2019
IP's GCF business creates safe, high-quality absorbent pulp for a wide range of applications like feminine care, incontinence and other personal care products that promote health and wellness. In addition, its specialty pulp serves as a sustainable raw material used in textiles, construction materials, paints, coatings and more. The GCF business generated $2.9B in revenue in 2023 and has operations in three countries, with eight mills and two converting facilities. "International Paper is committed to maximizing value for our shareholders, and to that end, we have launched a comprehensive and thorough review of strategic options for our global cellulose fibers business," said International Paper Chairman and CEO Andy Silvernail.
Third Quarter 2021 Summary *Reported sales grew 9%, primarily driven by double-digit core sales growth in Beauty + Home and Food + Beverage from a combination of price increases and volume growth *Core sales (excluding currency effects) increased 8% *Pharma sales declined slightly compared to the prior year *Reported net income totaled $47 million *Acquisition Updates: -Completed the acquisition of 80% of Weihai Hengyu Medical Products, adding elastomeric and plastic component manufacturing capabilities in China for injectable drug delivery -Completed the acquisition of a majority stake in Voluntis, a provider of digital therapeutic solutions